Compounds of formulae (IA) and (IB):
wherein R1, R2, R3, Ar1 and X are as defined above, are endothelin antagonists. The compounds are therefore useful in the treatment of a variety of conditions mediated by endothelin, such as restenosis, renal failure and systemic and pulmonary hypertension.
Compounds of formulae (IA) and (IB):
wherein R1, R2, R3, Ar1 and X are as defined above, are endothelin antagonists. The compounds are therefore useful in the treatment of a variety of conditions mediated by endothelin, such as restenosis, renal failure and systemic and pulmonary hypertension.
式(IA)和(IB)的化合物:
其中 R1、R2、R3、Ar1 和 X 如上文所定义,是内皮素拮抗剂。因此,这些化合物可用于治疗由内皮素介导的各种疾病,如血管再狭窄、肾功能衰竭、全身性和肺性高血压。
US6573270B1
申请人:——
公开号:US6573270B1
公开(公告)日:2003-06-03
US6962923B2
申请人:——
公开号:US6962923B2
公开(公告)日:2005-11-08
Pyrazole compositions
申请人:Pfizer Inc.
公开号:US20030232848A1
公开(公告)日:2003-12-18
Compounds of formulae (IA) and (IB):
1
wherein R
1
, R
2
, R
3
, Ar
1
and X are as defined above, are endothelin antagonists. The compounds are therefore useful in the treatment of a variety of conditions mediated by endothelin, such as restenosis, renal failure and systemic and pulmonary hypertension.